BACKGROUND: Cerebral microbleeds (CMBs) are a common vascular pathology associated with future intracerebral hemorrhage. Plasma biomarkers of amyloid, tau, and neurodegeneration may provide a screening avenue to identify those with CMBs, but evidence is conflicting. OBJECTIVE: To determine the association between plasma biomarkers (Aβ40, Aβ42, t-tau, p-tau181, p-tau217, neurofilament light chain (NfL)) and CMBs in a population-based study of aging and whether these biomarkers predict higher signal on Aβ-PET imaging in patients with multiple CMBs. METHODS: 712 participants from the Mayo Clinic Study of Aging with T2* GRE MRI and plasma biomarkers were included. Biomarkers were analyzed utilizing Simoa (Aβ40, Aβ42, t-tau, NfL) or Meso Scale Discovery (p-tau181, p-tau217) platforms. Cross-sectional associations between CMBs, plasma biomarkers and Aβ-PET were evaluated using hurdle models and multivariable regression models. RESULTS: Among the 188 (26%) individuals with≥1 CMB, a lower plasma Aβ42/Aβ40 ratio was associated with more CMBs after adjusting for covariables (IRR 568.5 95% CI 2.8-116,127). No other biomarkers were associated with risk or number CMBs. In 81 individuals with≥2 CMBs, higher plasma t-tau, p-tau181, and p-tau217 all were associated with higher Aβ-PET signal, with plasma p-tau217 having the strongest predictive value (r2 0.603, AIC -53.0). CONCLUSION: Lower plasma Aβ42/Aβ40 ratio and higher plasma p-tau217 were associated with brain amyloidosis in individuals with CMBs from the general population. Our results suggest that in individuals with multiple CMBs and/or lobar intracranial hemorrhage that a lower plasma Aβ42/Aβ40 ratio or elevated p-tau217 may indicate underlying cerebral amyloid angiopathy.
BACKGROUND: Cerebral microbleeds (CMBs) are a common vascular pathology associated with future intracerebral hemorrhage. Plasma biomarkers of amyloid, tau, and neurodegeneration may provide a screening avenue to identify those with CMBs, but evidence is conflicting. OBJECTIVE: To determine the association between plasma biomarkers (Aβ40, Aβ42, t-tau, p-tau181, p-tau217, neurofilament light chain (NfL)) and CMBs in a population-based study of aging and whether these biomarkers predict higher signal on Aβ-PET imaging in patients with multiple CMBs. METHODS: 712 participants from the Mayo Clinic Study of Aging with T2* GRE MRI and plasma biomarkers were included. Biomarkers were analyzed utilizing Simoa (Aβ40, Aβ42, t-tau, NfL) or Meso Scale Discovery (p-tau181, p-tau217) platforms. Cross-sectional associations between CMBs, plasma biomarkers and Aβ-PET were evaluated using hurdle models and multivariable regression models. RESULTS: Among the 188 (26%) individuals with≥1 CMB, a lower plasma Aβ42/Aβ40 ratio was associated with more CMBs after adjusting for covariables (IRR 568.5 95% CI 2.8-116,127). No other biomarkers were associated with risk or number CMBs. In 81 individuals with≥2 CMBs, higher plasma t-tau, p-tau181, and p-tau217 all were associated with higher Aβ-PET signal, with plasma p-tau217 having the strongest predictive value (r2 0.603, AIC -53.0). CONCLUSION: Lower plasma Aβ42/Aβ40 ratio and higher plasma p-tau217 were associated with brain amyloidosis in individuals with CMBs from the general population. Our results suggest that in individuals with multiple CMBs and/or lobar intracranial hemorrhage that a lower plasma Aβ42/Aβ40 ratio or elevated p-tau217 may indicate underlying cerebral amyloid angiopathy.
Entities:
Keywords:
Amyloid-β; PiB-PET; biomarker; cerebral microbleed; plasma; tau
Authors: Mar Hernandez-Guillamon; Pilar Delgado; Anna Penalba; David Rodriguez-Luna; Carlos A Molina; Alex Rovira; José Alvarez-Sabin; Mercè Boada; Joan Montaner Journal: Neurodegener Dis Date: 2012-01-17 Impact factor: 2.977
Authors: S M Greenberg; H S Cho; H C O'Donnell; J Rosand; A Z Segal; L H Younkin; S G Younkin; G W Rebeck Journal: Ann N Y Acad Sci Date: 2000-04 Impact factor: 5.691
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström Journal: Ann Neurol Date: 2004-03 Impact factor: 10.422
Authors: Dimitri Renard; Giovanni Castelnovo; Anne Wacongne; Anne Le Floch; Eric Thouvenot; Julie Mas; Audrey Gabelle; Pierre Labauge; Sylvain Lehmann Journal: J Neurol Date: 2012-05-11 Impact factor: 4.849
Authors: Jeremy A Syrjanen; Michelle R Campbell; Alicia Algeciras-Schimnich; Prashanthi Vemuri; Jonathan Graff-Radford; Mary M Machulda; Guojun Bu; David S Knopman; Clifford R Jack; Ronald C Petersen; Michelle M Mielke Journal: Alzheimers Dement Date: 2021-09-27 Impact factor: 16.655
Authors: Shorena Janelidze; Erik Stomrud; Sebastian Palmqvist; Henrik Zetterberg; Danielle van Westen; Andreas Jeromin; Linan Song; David Hanlon; Cristina A Tan Hehir; David Baker; Kaj Blennow; Oskar Hansson Journal: Sci Rep Date: 2016-05-31 Impact factor: 4.379
Authors: Steffi De Meyer; Jolien M Schaeverbeke; Inge M W Verberk; Benjamin Gille; Maxim De Schaepdryver; Emma S Luckett; Silvy Gabel; Rose Bruffaerts; Kimberley Mauroo; Elisabeth H Thijssen; Erik Stoops; Hugo M Vanderstichele; Charlotte E Teunissen; Rik Vandenberghe; Koen Poesen Journal: Alzheimers Res Ther Date: 2020-12-05 Impact factor: 6.982